Acadian Asset Management LLC bought a new position in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 4,200 shares of the company’s stock, valued at approximately $88,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Comerica Bank lifted its holdings in Amphastar Pharmaceuticals by 2.1% during the 1st quarter. Comerica Bank now owns 34,703 shares of the company’s stock worth $730,000 after buying an additional 722 shares during the period. Texas Permanent School Fund lifted its holdings in Amphastar Pharmaceuticals by 3.8% during the 1st quarter. Texas Permanent School Fund now owns 23,475 shares of the company’s stock worth $480,000 after buying an additional 851 shares during the period. JPMorgan Chase & Co. lifted its holdings in Amphastar Pharmaceuticals by 15.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock worth $205,000 after buying an additional 1,314 shares during the period. Swiss National Bank lifted its holdings in Amphastar Pharmaceuticals by 2.2% during the 2nd quarter. Swiss National Bank now owns 64,400 shares of the company’s stock worth $1,359,000 after buying an additional 1,400 shares during the period. Finally, Arizona State Retirement System lifted its holdings in Amphastar Pharmaceuticals by 2.7% during the 2nd quarter. Arizona State Retirement System now owns 54,756 shares of the company’s stock worth $1,156,000 after buying an additional 1,422 shares during the period. 47.26% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CEO Jack Y. Zhang sold 300,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $20.82, for a total value of $6,246,000.00. Following the transaction, the chief executive officer now directly owns 2,147,316 shares of the company’s stock, valued at approximately $44,707,119.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Yakob Liawatidewi sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $20.73, for a total value of $103,650.00. Following the completion of the transaction, the senior vice president now directly owns 47,188 shares in the company, valued at $978,207.24. The disclosure for this sale can be found here. Insiders sold a total of 339,454 shares of company stock worth $7,084,842 over the last three months. 30.80% of the stock is owned by company insiders.
Shares of NASDAQ:AMPH opened at $21.62 on Friday. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of 102.95 and a beta of 1.17. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.81 and a quick ratio of 1.83. The business’s 50-day moving average is $21.12 and its 200-day moving average is $21.15. Amphastar Pharmaceuticals Inc has a 1 year low of $17.71 and a 1 year high of $25.43.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.05. The company had revenue of $79.00 million for the quarter, compared to the consensus estimate of $78.90 million. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.03 EPS. Analysts anticipate that Amphastar Pharmaceuticals Inc will post 0.15 EPS for the current year.
AMPH has been the topic of a number of recent analyst reports. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research note on Wednesday, July 10th. TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, August 7th. BidaskClub downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Wells Fargo & Co set a $29.00 price objective on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 6th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $24.64.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Recommended Story: Stock Split
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.